On 17 February 2016, the European Centre for Disease Prevention and Control (ECDC), launched a public consultation on the use of oseltamivir and zanamivir.

Following a consultation with international public health experts, convened in Stockholm in February 2015 to review data presented in newly conducted systematic reviews and meta-analyses of clinical studies on influenza antivirals [1–3], an ECDC expert opinion was developed. This opinion has now been published on the ECDC website and is open for comments until 17 March 2016.

Oseltamivir and zanamivir, neuraminidase inhibitors, are currently authorised in the EU and the European Economic Area for treatment and prophylaxis of influenza disease. The drugs have been the subject of debate concerning their effectiveness and safety, and the appropriateness of stockpiling these drugs for use in future influenza pandemics has also been discussed.

Read more here.

References

License and copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the European Centre for Disease Prevention and Control, 2016.